Please assess the completion status of the following clinical trial:

Trial Title: Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Admitted to an ICU~* Expected to require admission to an ICU for ≥ 48 hours~* Intravenous opioid administration in the prior 24 hours of ≥ 100 mcg fentanyl equivalents~Exclusion Criteria:~* Scheduled use of an opioid ≥ 10 mg morphine equivalents per day in the week prior to ICU admission~* History of constipation (≤ 2 SBM per week and current use of stool softener or laxative therapy) prior to ICU admission~* Current scheduled use of a medication affecting gastric motility~* Current use of a medication known to be a strong CYP3A4 inhibitor~* History of a neurologic condition that may affect the permeability of the blood-brain barrier~* Acute GI condition (e.g., clinical evidence of acute fecal impaction/complete obstruction, acute surgical abdomen, acute GI bleeding)~* Condition affecting GI motility or function (e.g. inflammatory bowel disease requiring immunosuppressive therapy, symptomatic Clostridium difficile, active diverticular disease, surgery on the colon or abdomen within 60 days of ICU admission)~* Current use of total parenteral nutrition~* Administration of enteral nutrition through a jejunal tube~* Severe hepatic dysfunction~* Endstage renal disease defined as either i. calculated creatinine clearance ≤ 10ml/min or ii. Any current use of renal replacement therapy~* Inability to enroll in study and initiate study medication within 48 hours of the patient begin first initiated on scheduled IV opioid therapy after ICU admission~* Unreliable method for enteral, gastric and/or oral medication administration (e.g., no feeding tube, nasogastric tube is on suction)~* Current or previous use of an opioid antagonist agent (e.g., naloxegol, methylnaltrexone) in the past 30 days~* Pregnant or actively lactating females~* Current participation in another interventional clinical study~* Inability to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naloxegol Oral Tablet (Type: EXPERIMENTAL): Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:~1. Adverse event potentially attributable to the study drug.~2. Use of Relistor.~3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~4. The participant has been administered 10 days of study medication.~5. The participant is discharged from the ICU.~6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:~1. Adverse event potentially attributable to the study drug.~2. Use of Relistor.~3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~4. The participant has been administered 10 days of study medication.~5. The participant is discharged from the ICU.~6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).